false FY 0001581178 NY 0001581178 2024-01-01 2024-12-31 0001581178 2024-12-31 0001581178 2023-12-31 0001581178 2023-01-01 2023-12-31 0001581178 2022-12-31 0001581178 us-gaap:EmployeeStockOptionMember eprx:AmendedPlanMember 2023-12-31 0001581178 eprx:BioTalentCanadaMember 2023-12-31 0001581178 eprx:NRCIRAPSpecifiedResearchAndDevelopmentFundingActivitiesMember 2023-12-31 0001581178 eprx:ExcerciseOfWarrantsMember 2023-12-31 0001581178 eprx:CurrencyRiskMember 2023-12-31 0001581178 currency:CAD 2023-12-31 0001581178 currency:CAD eprx:CurrencyRiskMember 2023-12-31 0001581178 eprx:LabEquipmentMember 2023-12-31 0001581178 us-gaap:ComputerEquipmentMember 2023-12-31 0001581178 us-gaap:FurnitureAndFixturesMember 2023-12-31 0001581178 us-gaap:LeaseholdImprovementsMember 2023-12-31 0001581178 eprx:AmendedAndRestatedLicenseAgreementMember eprx:EupraxiaUsaMember srt:MaximumMember 2024-12-31 0001581178 eprx:AmendedAndRestatedLicenseAgreementMember eprx:EupraxiaUsaMember eprx:FirstOaRegulatoryApprovalMember srt:MaximumMember 2024-12-31 0001581178 eprx:AmendedAndRestatedLicenseAgreementMember eprx:EupraxiaUsaMember eprx:SalesThresholdIncludingLicensesAndSublicensesExceedingFiftyCroresMember srt:MaximumMember 2024-12-31 0001581178 eprx:AmendedAndRestatedLicenseAgreementMember eprx:EupraxiaUsaMember eprx:SecondOaRegulatoryApprovalMember srt:MaximumMember 2024-12-31 0001581178 eprx:AmendedAndRestatedLicenseAgreementMember eprx:EupraxiaUsaMember eprx:NonOaIndicationRegulatoryApprovalMember srt:MaximumMember 2024-12-31 0001581178 eprx:AmendedPlanMember eprx:May132024Member 2024-12-31 0001581178 eprx:AmendedPlanMember eprx:May282024Member 2024-12-31 0001581178 eprx:AmendedPlanMember eprx:Aug92024Member 2024-12-31 0001581178 eprx:AmendedPlanMember eprx:Nov252024Member 2024-12-31 0001581178 eprx:AmendedPlanMember eprx:Dec102024Member 2024-12-31 0001581178 eprx:AmendedPlanMember 2024-12-31 0001581178 eprx:AmendedPlanMember eprx:ThirtyFirstMarchTwoThousandAndTwentyTwoMember 2024-12-31 0001581178 eprx:AmendedPlanMember eprx:NineDecemberTwoThousandAndTwentyTwoMember 2024-12-31 0001581178 eprx:AmendedPlanMember eprx:EighteenthMayTwoThousandAndTwentyThreeMember 2024-12-31 0001581178 eprx:AmendedPlanMember eprx:ThirtyMayTwoThousandAndTwentyThreeMember 2024-12-31 0001581178 eprx:AmendedPlanMember eprx:TwentySeventhSeptemberTwoThousandAndTwentyThreeMember 2024-12-31 0001581178 eprx:AmendedPlanMember eprx:FiveMarchTwoThousandAndEighteenMember 2024-12-31 0001581178 eprx:AmendedPlanMember eprx:NineMarchTwoThousandAndTwentyOneMember 2024-12-31 0001581178 eprx:AmendedPlanMember eprx:NineMarchTwoThousandAndTwentyOne1Member 2024-12-31 0001581178 eprx:AmendedPlanMember eprx:ThreeMayTwoThousandAndTwentyOneMember 2024-12-31 0001581178 eprx:AmendedPlanMember eprx:TwentySeventhSeptemberTwoThousandAndFifteenMember 2024-12-31 0001581178 eprx:AmendedPlanMember eprx:TwoNovemberTwoThousandAndFifteenMember 2024-12-31 0001581178 eprx:AmendedPlanMember eprx:NineDecemberTwoThousandAndTwentyOneMember 2024-12-31 0001581178 us-gaap:EmployeeStockOptionMember eprx:AmendedPlanMember 2024-12-31 0001581178 eprx:BioTalentCanadaMember 2024-12-31 0001581178 eprx:NRCIRAPSpecifiedResearchAndDevelopmentFundingActivitiesMember 2024-12-31 0001581178 eprx:ExcerciseOfWarrantsMember 2024-12-31 0001581178 country:CA 2024-12-31 0001581178 country:CA eprx:TaxYear2042Member 2024-12-31 0001581178 country:CA eprx:TaxYear2041Member 2024-12-31 0001581178 country:US eprx:TaxYear2035Member 2024-12-31 0001581178 country:AU eprx:TaxYear2034Member 2024-12-31 0001581178 country:US eprx:TaxYear2034Member 2024-12-31 0001581178 country:AU eprx:TaxYear2033Member 2024-12-31 0001581178 country:US eprx:TaxYear2033Member 2024-12-31 0001581178 country:AU eprx:TaxYear2032Member 2024-12-31 0001581178 country:US eprx:TaxYear2040Member 2024-12-31 0001581178 country:AU eprx:TaxYear2039Member 2024-12-31 0001581178 country:US eprx:TaxYear2039Member 2024-12-31 0001581178 country:AU eprx:TaxYear2036Member 2024-12-31 0001581178 country:US eprx:TaxYear2036Member 2024-12-31 0001581178 country:AU eprx:TaxYear2035Member 2024-12-31 0001581178 country:CA eprx:TaxYear2043Member 2024-12-31 0001581178 country:AU eprx:TaxYear2042Member 2024-12-31 0001581178 country:US eprx:TaxYear2042Member 2024-12-31 0001581178 country:AU eprx:TaxYear2041Member 2024-12-31 0001581178 country:US eprx:TaxYear2041Member 2024-12-31 0001581178 country:AU eprx:TaxYear2040Member 2024-12-31 0001581178 country:AU 2024-12-31 0001581178 country:US 2024-12-31 0001581178 country:AU eprx:TaxYearAfter2044Member 2024-12-31 0001581178 country:US eprx:TaxYearAfter2044Member 2024-12-31 0001581178 country:CA eprx:TaxYearAfter2044Member 2024-12-31 0001581178 country:AU eprx:TaxYear2043Member 2024-12-31 0001581178 country:CA eprx:TaxYear2040Member 2024-12-31 0001581178 country:CA eprx:TaxYear2039Member 2024-12-31 0001581178 country:CA eprx:TaxYear2036Member 2024-12-31 0001581178 country:CA eprx:TaxYear2035Member 2024-12-31 0001581178 country:CA eprx:TaxYear2034Member 2024-12-31 0001581178 country:CA eprx:TaxYear2033Member 2024-12-31 0001581178 country:US eprx:TaxYear2043Member 2024-12-31 0001581178 country:CA eprx:TaxYear2044Member 2024-12-31 0001581178 country:US eprx:TaxYear2044Member 2024-12-31 0001581178 country:AU eprx:TaxYear2044Member 2024-12-31 0001581178 country:CA eprx:TaxYear2037Member 2024-12-31 0001581178 country:CA eprx:TaxYear2038Member 2024-12-31 0001581178 country:US eprx:TaxYear2037Member 2024-12-31 0001581178 country:US eprx:TaxYear2038Member 2024-12-31 0001581178 country:AU eprx:TaxYear2037Member 2024-12-31 0001581178 country:AU eprx:TaxYear2038Member 2024-12-31 0001581178 country:US eprx:TaxYear2032Member 2024-12-31 0001581178 country:AU eprx:TaxYear2031Member 2024-12-31 0001581178 country:US eprx:TaxYear2031Member 2024-12-31 0001581178 country:CA eprx:TaxYear2031Member 2024-12-31 0001581178 country:CA eprx:TaxYear2032Member 2024-12-31 0001581178 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:CanadaRevenueAgencyMember 2024-12-31 0001581178 us-gaap:CanadaRevenueAgencyMember eprx:ProvincialInvestmentTaxCreditsMember 2024-12-31 0001581178 us-gaap:CanadaRevenueAgencyMember eprx:CanadianFederalInvestmentTaxCreditsMember 2024-12-31 0001581178 eprx:CurrencyRiskMember 2024-12-31 0001581178 currency:CAD 2024-12-31 0001581178 currency:CAD eprx:CurrencyRiskMember 2024-12-31 0001581178 eprx:ExpiryPeriodThreeMember 2024-12-31 0001581178 eprx:ExpiryPeriodSevenMember 2024-12-31 0001581178 eprx:ExpiryPeriodSixMember 2024-12-31 0001581178 eprx:ExpiryPeriodFiveMember 2024-12-31 0001581178 eprx:ExpiryPeriodFourMember 2024-12-31 0001581178 eprx:ExpiryPeriodTwoMember 2024-12-31 0001581178 eprx:ExpiryPeriodOneMember 2024-12-31 0001581178 srt:SubsidiariesMember eprx:EupraxiaHoldingsIncMember 2024-12-31 0001581178 srt:SubsidiariesMember eprx:EupraxiaPharmaceuticalsUsaLlcMember 2024-12-31 0001581178 srt:SubsidiariesMember eprx:AmdmHoldingsIncMember 2024-12-31 0001581178 srt:SubsidiariesMember eprx:EupraxiaPharmaIncMember 2024-12-31 0001581178 srt:SubsidiariesMember eprx:EupraxiaPharmaceuticalsAustraliaPtyLtdMember 2024-12-31 0001581178 srt:SubsidiariesMember eprx:EupraxiaPharmaUsaIncMember 2024-12-31 0001581178 us-gaap:ComputerEquipmentMember 2024-12-31 0001581178 us-gaap:FurnitureAndFixturesMember 2024-12-31 0001581178 us-gaap:LeaseholdImprovementsMember 2024-12-31 0001581178 eprx:LabEquipmentMember 2024-12-31 0001581178 eprx:WarrantsGrantedAsPartOfShareBasedPaymentArrangementMember eprx:ExpiryPeriodThreeMember 2024-12-31 0001581178 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2023-01-01 2023-12-31 0001581178 us-gaap:PrivatePlacementMember 2023-01-01 2023-12-31 0001581178 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0001581178 eprx:ExcerciseOfWarrantsMember us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001581178 eprx:ExcerciseOfWarrantsMember us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0001581178 eprx:ExcerciseOfWarrantsMember 2023-01-01 2023-12-31 0001581178 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001581178 us-gaap:NoncontrollingInterestMember 2023-01-01 2023-12-31 0001581178 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0001581178 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-12-31 0001581178 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-12-31 0001581178 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-12-31 0001581178 us-gaap:ConvertibleDebtMember eprx:LoanMember 2023-01-01 2023-12-31 0001581178 eprx:AmendedPlanMember 2023-01-01 2023-12-31 0001581178 us-gaap:EmployeeStockOptionMember eprx:AmendedPlanMember 2023-01-01 2023-12-31 0001581178 eprx:NRCIRAPSpecifiedResearchAndDevelopmentFundingActivitiesMember 2023-01-01 2023-12-31 0001581178 eprx:CanadianPrimeRateMember eprx:SiliconValleyBankMember us-gaap:ConvertibleDebtMember srt:MinimumMember 2023-01-01 2023-12-31 0001581178 eprx:CanadianPrimeRateMember eprx:SiliconValleyBankMember us-gaap:ConvertibleDebtMember srt:MaximumMember 2023-01-01 2023-12-31 0001581178 eprx:CanadianPrimeRateMember eprx:SiliconValleyBankMember us-gaap:ConvertibleDebtMember 2023-01-01 2023-12-31 0001581178 eprx:ManufacturingAndAnalyticaMember 2023-01-01 2023-12-31 0001581178 eprx:RegulatoryMember 2023-01-01 2023-12-31 0001581178 eprx:PreClinicalMember 2023-01-01 2023-12-31 0001581178 eprx:ClinicalMember 2023-01-01 2023-12-31 0001581178 eprx:WarrantsGrantedAsPartOfShareBasedPaymentArrangementMember 2023-01-01 2023-12-31 0001581178 eprx:ExcerciseOfOptionsMember 2023-01-01 2023-12-31 0001581178 us-gaap:ComputerEquipmentMember 2023-01-01 2023-12-31 0001581178 eprx:LabEquipmentMember 2023-01-01 2023-12-31 0001581178 us-gaap:FurnitureAndFixturesMember 2023-01-01 2023-12-31 0001581178 us-gaap:LeaseholdImprovementsMember 2023-01-01 2023-12-31 0001581178 eprx:EP104IARMember 2023-01-01 2023-12-31 0001581178 eprx:EP104GIMember 2023-01-01 2023-12-31 0001581178 eprx:PreClinicalMember 2023-01-01 2023-12-31 0001581178 dei:BusinessContactMember 2024-01-01 2024-12-31 0001581178 eprx:OvernightMarketedPublicOfferingMember 2024-01-01 2024-12-31 0001581178 us-gaap:PrivatePlacementMember 2024-01-01 2024-12-31 0001581178 us-gaap:PreferredStockMember us-gaap:PrivatePlacementMember 2024-01-01 2024-12-31 0001581178 us-gaap:CommonStockMember eprx:OvernightMarketedPublicOfferingMember 2024-01-01 2024-12-31 0001581178 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-12-31 0001581178 eprx:ExcerciseOfWarrantsMember us-gaap:CommonStockMember 2024-01-01 2024-12-31 0001581178 eprx:ExcerciseOfWarrantsMember us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-12-31 0001581178 eprx:ExcerciseOfWarrantsMember 2024-01-01 2024-12-31 0001581178 us-gaap:CommonStockMember 2024-01-01 2024-12-31 0001581178 us-gaap:RetainedEarningsMember 2024-01-01 2024-12-31 0001581178 us-gaap:NoncontrollingInterestMember 2024-01-01 2024-12-31 0001581178 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-12-31 0001581178 us-gaap:PreferredStockMember 2024-01-01 2024-12-31 0001581178 srt:MaximumMember 2024-01-01 2024-12-31 0001581178 srt:MinimumMember 2024-01-01 2024-12-31 0001581178 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-12-31 0001581178 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-12-31 0001581178 eprx:AmendedAndRestatedLicenseAgreementMember eprx:EupraxiaUsaMember 2024-01-01 2024-12-31 0001581178 eprx:AmendedAndRestatedLicenseAgreementMember eprx:EupraxiaUsaMember srt:MaximumMember 2024-01-01 2024-12-31 0001581178 eprx:AmendedAndRestatedLicenseAgreementMember eprx:EupraxiaUsaMember srt:MinimumMember 2024-01-01 2024-12-31 0001581178 eprx:AmendedAndRestatedLicenseAgreementMember eprx:EupraxiaUsaMember srt:ArithmeticAverageMember 2024-01-01 2024-12-31 0001581178 eprx:PriorToSuccessfulCompletionOfPhaseTwoBStudyMember 2024-01-01 2024-12-31 0001581178 eprx:AfterSuccessfulCompletionOfPhaseTwoBStudyButPriorToSuccessfulCompletionOfPhaseThreeStudyMember 2024-01-01 2024-12-31 0001581178 eprx:AfterSuccessfulCompletionOfPhaseThreeStudyButPriorToRegulatoryApprovalOfTheProductFromFdaInTheUnitedStatusMember 2024-01-01 2024-12-31 0001581178 eprx:AfterRegulatoryApprovalOfTheProductFromFdaInTheUnitedStatesMember 2024-01-01 2024-12-31 0001581178 us-gaap:ConvertibleDebtMember eprx:LoanMember 2024-01-01 2024-12-31 0001581178 eprx:AmendedPlanMember 2024-01-01 2024-12-31 0001581178 eprx:AmendedPlanMember eprx:NineDecemberTwoThousandAndTwentyOneMember 2024-01-01 2024-12-31 0001581178 eprx:AmendedPlanMember eprx:ThirtyFirstMarchTwoThousandAndTwentyTwoMember 2024-01-01 2024-12-31 0001581178 eprx:AmendedPlanMember eprx:NineDecemberTwoThousandAndTwentyTwoMember 2024-01-01 2024-12-31 0001581178 eprx:AmendedPlanMember eprx:EighteenthMayTwoThousandAndTwentyThreeMember 2024-01-01 2024-12-31 0001581178 eprx:AmendedPlanMember eprx:ThirtyMayTwoThousandAndTwentyThreeMember 2024-01-01 2024-12-31 0001581178 eprx:AmendedPlanMember eprx:TwentySeventhSeptemberTwoThousandAndTwentyThreeMember 2024-01-01 2024-12-31 0001581178 eprx:AmendedPlanMember eprx:TwentySeventhSeptemberTwoThousandAndFifteenMember 2024-01-01 2024-12-31 0001581178 eprx:AmendedPlanMember eprx:TwoNovemberTwoThousandAndFifteenMember 2024-01-01 2024-12-31 0001581178 eprx:AmendedPlanMember eprx:FiveMarchTwoThousandAndEighteenMember 2024-01-01 2024-12-31 0001581178 eprx:AmendedPlanMember eprx:NineMarchTwoThousandAndTwentyOneMember 2024-01-01 2024-12-31 0001581178 eprx:AmendedPlanMember eprx:NineMarchTwoThousandAndTwentyOne1Member 2024-01-01 2024-12-31 0001581178 eprx:AmendedPlanMember eprx:ThreeMayTwoThousandAndTwentyOneMember 2024-01-01 2024-12-31 0001581178 eprx:AmendedPlanMember eprx:May132024Member 2024-01-01 2024-12-31 0001581178 eprx:AmendedPlanMember eprx:May282024Member 2024-01-01 2024-12-31 0001581178 eprx:AmendedPlanMember eprx:Aug92024Member 2024-01-01 2024-12-31 0001581178 eprx:AmendedPlanMember eprx:Nov252024Member 2024-01-01 2024-12-31 0001581178 eprx:AmendedPlanMember eprx:Dec102024Member 2024-01-01 2024-12-31 0001581178 us-gaap:EmployeeStockOptionMember eprx:AmendedPlanMember 2024-01-01 2024-12-31 0001581178 eprx:NRCIRAPSpecifiedResearchAndDevelopmentFundingActivitiesMember 2024-01-01 2024-12-31 0001581178 eprx:CanadianPrimeRateMember eprx:SiliconValleyBankMember us-gaap:ConvertibleDebtMember srt:MinimumMember 2024-01-01 2024-12-31 0001581178 eprx:CanadianPrimeRateMember eprx:SiliconValleyBankMember us-gaap:ConvertibleDebtMember srt:MaximumMember 2024-01-01 2024-12-31 0001581178 eprx:CanadianPrimeRateMember eprx:SiliconValleyBankMember us-gaap:ConvertibleDebtMember 2024-01-01 2024-12-31 0001581178 srt:SubsidiariesMember eprx:EupraxiaPharmaUsaIncMember 2024-01-01 2024-12-31 0001581178 srt:SubsidiariesMember eprx:EupraxiaPharmaceuticalsAustraliaPtyLtdMember 2024-01-01 2024-12-31 0001581178 srt:SubsidiariesMember eprx:EupraxiaPharmaIncMember 2024-01-01 2024-12-31 0001581178 srt:SubsidiariesMember eprx:AmdmHoldingsIncMember 2024-01-01 2024-12-31 0001581178 srt:SubsidiariesMember eprx:EupraxiaPharmaceuticalsUsaLlcMember 2024-01-01 2024-12-31 0001581178 srt:SubsidiariesMember eprx:EupraxiaHoldingsIncMember 2024-01-01 2024-12-31 0001581178 eprx:RegulatoryMember 2024-01-01 2024-12-31 0001581178 eprx:PreClinicalMember 2024-01-01 2024-12-31 0001581178 eprx:ClinicalMember 2024-01-01 2024-12-31 0001581178 eprx:ManufacturingAndAnalyticaMember 2024-01-01 2024-12-31 0001581178 us-gaap:CanadaRevenueAgencyMember eprx:CanadianFederalInvestmentTaxCreditsMember 2024-01-01 2024-12-31 0001581178 us-gaap:CanadaRevenueAgencyMember eprx:ProvincialInvestmentTaxCreditsMember 2024-01-01 2024-12-31 0001581178 eprx:WarrantsGrantedAsPartOfShareBasedPaymentArrangementMember 2024-01-01 2024-12-31 0001581178 eprx:ExpiryPeriodOneMember 2024-01-01 2024-12-31 0001581178 eprx:ExpiryPeriodTwoMember 2024-01-01 2024-12-31 0001581178 eprx:ExpiryPeriodThreeMember 2024-01-01 2024-12-31 0001581178 eprx:ExpiryPeriodFourMember 2024-01-01 2024-12-31 0001581178 eprx:ExpiryPeriodFiveMember 2024-01-01 2024-12-31 0001581178 eprx:ExpiryPeriodSixMember 2024-01-01 2024-12-31 0001581178 eprx:ExpiryPeriodSevenMember 2024-01-01 2024-12-31 0001581178 eprx:ExcerciseOfOptionsMember 2024-01-01 2024-12-31 0001581178 us-gaap:ComputerEquipmentMember 2024-01-01 2024-12-31 0001581178 us-gaap:FurnitureAndFixturesMember 2024-01-01 2024-12-31 0001581178 eprx:LabEquipmentMember 2024-01-01 2024-12-31 0001581178 us-gaap:LeaseholdImprovementsMember 2024-01-01 2024-12-31 0001581178 eprx:WarrantsGrantedAsPartOfShareBasedPaymentArrangementMember eprx:ExpiryPeriodThreeMember 2024-01-01 2024-12-31 0001581178 eprx:SiliconValleyBankMember 2024-01-01 2024-12-31 0001581178 us-gaap:ConvertiblePreferredStockMember 2024-01-01 2024-12-31 0001581178 eprx:QuarterMember eprx:PikPreferredSharesMember eprx:ShareholderApprovedMember 2024-01-01 2024-12-31 0001581178 eprx:QuarterMember eprx:ShareholderNotApprovedMember 2024-01-01 2024-12-31 0001581178 eprx:AnnualMember eprx:PikPreferredSharesMember eprx:ShareholderApprovedMember 2024-01-01 2024-12-31 0001581178 eprx:AnnualMember eprx:ShareholderNotApprovedMember 2024-01-01 2024-12-31 0001581178 eprx:EP104IARMember 2024-01-01 2024-12-31 0001581178 eprx:EP104GIMember 2024-01-01 2024-12-31 0001581178 eprx:PreClinicalMember 2024-01-01 2024-12-31 0001581178 eprx:AmendedAndRestatedLicenseAgreementMember eprx:EupraxiaUsaMember us-gaap:ResearchAndDevelopmentExpenseMember eprx:SuccessfulCompletionOfPhaseTwoBStudyMember 2024-01-01 2024-12-31 0001581178 srt:ScenarioPreviouslyReportedMember 2024-01-01 2024-12-31 0001581178 us-gaap:LoansPayableMember 2021-09-10 0001581178 us-gaap:LoansPayableMember 2021-09-13 0001581178 eprx:NRCIRAPSpecifiedResearchAndDevelopmentFundingActivitiesMember 2021-10-01 0001581178 us-gaap:LoansPayableMember 2021-10-01 0001581178 eprx:SiliconValleyBankMember us-gaap:ConvertibleDebtMember 2021-06-21 0001581178 eprx:CanadianPrimeRateMember eprx:SiliconValleyBankMember us-gaap:ConvertibleDebtMember 2021-12-31 0001581178 eprx:AmendedPlanMember 2021-12-31 0001581178 eprx:AmdmHoldingsMember eprx:EuphraxiaUsaMember 2021-12-31 0001581178 eprx:AmdmHoldingsMember eprx:EuphraxiaPharmaIncMember 2021-12-31 0001581178 eprx:EuphraxiaPharmaIncMember eprx:OutstandingOfAMDMHoldingsMember us-gaap:CommonClassAMember 2021-12-31 0001581178 eprx:EuphraxiaPharmaIncMember us-gaap:CommonClassAMember 2021-12-31 0001581178 eprx:AmdmHoldingsMember eprx:EuphraxiaPharmaIncMember eprx:ClassBNonVotingStockMember eprx:ChiefScientificOfficerMember 2021-12-31 0001581178 us-gaap:CommonStockMember 2023-08-18 2023-08-18 0001581178 us-gaap:PrivatePlacementMember 2023-08-18 2023-08-18 0001581178 us-gaap:PrivatePlacementMember 2023-08-18 0001581178 eprx:AmdmHoldingsMember eprx:EuphraxiaPharmaIncMember eprx:ClassBNonVotingStockMember eprx:ChiefScientificOfficerMember 2021-01-31 2021-01-31 0001581178 eprx:NRCIRAPSpecifiedResearchAndDevelopmentFundingActivitiesMember 2021-10-01 2021-10-01 0001581178 us-gaap:LoansPayableMember 2021-10-01 2021-10-01 0001581178 eprx:Series1PreferredStockMember us-gaap:IPOMember 2024-10-31 2024-10-31 0001581178 eprx:SiliconValleyBankMember us-gaap:ConvertibleDebtMember 2021-06-21 2021-06-21 0001581178 eprx:CanadianPrimeRateMember eprx:SiliconValleyBankMember us-gaap:ConvertibleDebtMember 2021-06-21 2021-06-21 0001581178 eprx:SiliconValleyBankMember us-gaap:ConvertibleDebtMember 2024-06-21 0001581178 eprx:SiliconValleyBankMember us-gaap:ConvertibleDebtMember 2024-09-11 0001581178 eprx:ConvertibleDebtFacilityMember 2024-08-01 0001581178 eprx:EupraxiaCommonSharesMember 2024-08-01 0001581178 eprx:ConvertibleDebtFacilityMember 2024-08-01 2024-08-01 0001581178 us-gaap:ConvertiblePreferredStockMember 2024-10-31 0001581178 us-gaap:EmployeeStockOptionMember eprx:AmendedPlanMember 2021-12-01 2021-12-31 0001581178 us-gaap:EmployeeStockOptionMember eprx:AmendedPlanMember us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2021-12-01 2021-12-31 0001581178 us-gaap:PrivatePlacementMember 2024-03-15 2024-03-15 0001581178 us-gaap:OverAllotmentOptionMember 2024-03-15 2024-03-15 0001581178 us-gaap:PrivatePlacementMember 2024-03-15 0001581178 us-gaap:SubsequentEventMember 2025-03-13 0001581178 us-gaap:SubsequentEventMember 2025-03-13 2025-03-13 0001581178 us-gaap:CommonStockMember 2022-12-31 0001581178 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001581178 us-gaap:RetainedEarningsMember 2022-12-31 0001581178 us-gaap:NoncontrollingInterestMember 2022-12-31 0001581178 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001581178 us-gaap:CommonStockMember 2023-12-31 0001581178 us-gaap:NoncontrollingInterestMember 2023-12-31 0001581178 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001581178 us-gaap:RetainedEarningsMember 2023-12-31 0001581178 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001581178 us-gaap:ComputerEquipmentMember 2022-12-31 0001581178 us-gaap:FurnitureAndFixturesMember 2022-12-31 0001581178 us-gaap:LeaseholdImprovementsMember 2022-12-31 0001581178 eprx:LabEquipmentMember 2022-12-31 0001581178 us-gaap:ConvertibleDebtMember eprx:LoanMember 2022-12-31 0001581178 eprx:AmendedPlanMember 2022-12-31 0001581178 eprx:AmendedPlanMember 2023-12-31 0001581178 eprx:WarrantsGrantedAsPartOfShareBasedPaymentArrangementMember 2022-12-31 0001581178 eprx:WarrantsGrantedAsPartOfShareBasedPaymentArrangementMember 2023-12-31 0001581178 us-gaap:ConvertibleDebtMember eprx:LoanMember 2023-12-31 0001581178 us-gaap:PreferredStockMember us-gaap:PrivatePlacementMember 2024-12-31 0001581178 us-gaap:CommonStockMember 2024-12-31 0001581178 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001581178 us-gaap:RetainedEarningsMember 2024-12-31 0001581178 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0001581178 us-gaap:NoncontrollingInterestMember 2024-12-31 0001581178 eprx:WarrantsGrantedAsPartOfShareBasedPaymentArrangementMember 2024-12-31 0001581178 us-gaap:ConvertibleDebtMember eprx:LoanMember 2024-12-31 xbrli:shares iso4217:USD xbrli:pure utr:Month utr:Year utr:sqft iso4217:CAD iso4217:AUD utr:Day iso4217:CAD xbrli:shares iso4217:USD xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
40-F

☐ | REGISTRATION STATEMENT PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934

☒ | ANNUAL REPORT PURSUANT TO SECTION 13(A) OR 15(D) OF THE SECU R ITIES EXCHANGE ACT OF 1934

For the fiscal year ended: December 31, 2024
Commission File Number:
001-41923
EUPRAXIA PHARMACEUTICALS INC.
(Exact name of registrant as specified in its charter)

British Columbia |  | 2834 |  | Not Applicable
(Province or other jurisdiction of incorporation or organization) |  | (Primary standard industrial classification code number, if applicable) |  | (I.R.S. Employer Identification No., if applicable)

201-2067
Cadboro Bay Road
Victoria, British Columbia, Canada V8R 5G4
Telephone: (250)
590-3968
(Address and telephone number of registrant’s principal executive offices)
Corporation Service Company
19 West 44th Street, Suite 200
New York,
NY
10036
(800)
927-9800
(Name, address (including zip code) and telephone number (including area code) of agent for service in the United States)
Securities registered pursuant to Section 12(b) of the Act:

Title of each class: |  | Trading Symbol(s): |  | Name of each exchange on which registered:
Common Shares, no par value |  | EPRX |  | The Nasdaq Stock Market LLC

Securities registered pursuant to Section 12(g) of the Act: None
Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act:
None
For annual reports, indicate by check mark the information filed with this form:

☒ Annual Information Form |  | ☒ Audited Annual Financial Statements

Indicate the number of outstanding shares of the issuer’s classes of capital or common stock as of the close of the period covered by the annual report: 35,641,603 Common Shares
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.Yes☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pur
su
ant to Rule 405 of Regulation
S-T
(s.232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files).Yes☒ No ☐
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule
12b-2
of the Exchange Act. Emerging growth company
.
☒
If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards† provided pursuant to Section 13(a) of the Exchange Act.☐

† | The term “new or revised financial accounting standard” refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012.

Indicate
by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.☐
If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.☒
Indicate
by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to
§240.10D-1(b).☐

Auditor Name: KPMG LLP |  | Auditor Location: Vancouver, Canada |  | Auditor Firm ID: 85

PRINCIPAL DOCUMENTS

The following documents are filed as part of this Annual Report on Form 40-F:

A. Annual Information Form

For the Registrant’s Annual Information Form (“AIF”) for the year ended December 31, 2024, see Exhibit 99.1 of this Annual Report on Form 40-F.

B. Audited Annual Financial Statements

For the Registrant’s Audited Consolidated Financial Statements as of and for the years ended December 31, 2024 and 2023 (the “2024 Financial Statements”), including the Independent Auditor’s Report with respect thereto, see Exhibit 99.2 of this Annual Report on Form 40-F.

C. Management’s Discussion and Analysis

For the Registrant’s Management’s Discussion and Analysis of Financial Condition and Results of Operations for the year ended December 31, 2024 (the “MD&A”), see Exhibit 99.3 of this Annual Report on Form 40-F.

CONTROLS AND PROCEDURES

A. Certifications

The required disclosure is included in Exhibits 99.5, 99.6, 99.7 and 99.8 of this Annual Report on Form 40-F.

B. Disclosure Controls and Procedures

The information provided under the heading “Disclosure Controls and Procedures and Internal Controls Over Financial Reporting” contained in the MD&A, filed as Exhibit 99.3 to this Annual Report on Form 40-F, is incorporated by reference herein.

C. Management’s Annual Report on Internal Control over Financial Reporting and Attestation Report of the Registered Public Accounting Firm

The information provided under the heading “Disclosure Controls and Procedures and Internal Controls Over Financial Reporting” contained in the MD&A, filed as Exhibit 99.3 to this Annual Report on Form 40-F, is incorporated by reference herein.

D. Changes in Internal Control over Financial Reporting

The information provided under the heading “Disclosure Controls and Procedures and Internal Controls Over Financial Reporting” contained in the MD&A, filed as Exhibit 99.3 to this Annual Report on Form 40-F, is incorporated by reference herein.

NOTICES PURSUANT TO REGULATION BTR

There were no notices required by Rule 104 of Regulation BTR that the Registrant sent during the year ended December 31, 2024 concerning any equity security subject to a blackout period under Rule 101 of Regulation BTR.

AUDIT COMMITTEE FINANCIAL EXPERT

The Registrant’s Board of Directors has determined that each member of the Audit Committee, John Montalbano, Simon Pimstone and Paul Geyer, are “independent” (as defined by Rule 10A-3 of the Exchange Act and Nasdaq Rule 5605(a)(2)) and that each of Mr. Montalbano and Dr. Pimstone are “audit committee financial experts” (as that term is defined in paragraph 8(b) of General Instruction B to Form 40-F). For a description of Mr. Montalbano’s and Dr. Pimstone’s relevant experience in financial matters, see the biographical descriptions for each under “Directors and Executive Officers” in the AIF, which is filed as Exhibit 99.1 to this Annual Report on Form 40-F.

The Commission has indicated that the designation or identification of a person as an audit committee financial expert does not make such person an “expert” for any purpose, impose any duties, obligations or liability on such person that are greater than those imposed on members of the audit committee and the board of directors who do not carry this designation or identification, or affect the duties, obligations or liability of any other member of the audit committee or board of directors.

CODE OF ETHICS

The Board of Directors of the Registrant (the “Board”) has adopted a written code of business conduct and ethics (the “Code”) which emphasizes the importance of matters relating to honest and ethical conduct, full, fair, accurate, timely, and understandable disclosure in reports that the Registrant files with, or submits to, the Commission and in other public communications, compliance with applicable laws, rules and regulations, the prompt internal reporting of violations of the Code and accountability for adherence to the Code. All individuals representing the Registrant, including the Registrant’s principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions, are expected to abide by all applicable provisions of the Code and adhere to its principles and values when representing the Registrant to the public or performing services for, or on behalf of, the Registrant. The Board will review the effectiveness of the Code on an ongoing basis to ensure that the Registrant’s business activities are conducted in accordance with the principles and rules set out therein. A copy of the Code can be obtained from the Registrant’s website at www.eupraxiapharma.com/investors.

PRINCIPAL ACCOUNTANT FEES AND SERVICES

The information provided under the heading “Audit Committee Information — External Auditor Service Fees by Category” contained in the AIF, filed as Exhibit 99.1 to this Annual Report on Form 40-F, is incorporated by reference herein.

AUDIT COMMITTEE PRE-APPROVAL POLICIES AND PROCEDURES

The information provided under the heading “Audit Committee Information — Pre-Approval Policies and Procedures” contained in the AIF, filed as Exhibit 99.1 to this Annual Report on Form 40-F, is incorporated by reference herein.

OFF-BALANCE SHEET ARRANGEMENTS

The information provided under the heading “Off-Balance Sheet Arrangements” contained in the MD&A, filed as Exhibit 99.3 to this Annual Report on Form 40-F, is incorporated by reference herein.

CONTRACTUAL OBLIGATIONS

The information provided under the heading “Contractual Obligations” contained in the MD&A, filed as Exhibit 99.3 to this Annual Report on Form 40-F, is incorporated by reference herein.

IDENTIFICATION OF THE AUDIT COMMITTEE

The information provided under the heading “Audit Committee Information — Audit Committee” contained in the AIF, filed as Exhibit 99.1 to this Annual Report on Form 40-F, is incorporated by reference herein.

DIFFERENCES IN NASDAQ AND CANADIAN CORPORATE GOVERNANCE REQUIREMENTS

The Registrant is a “foreign private issuer” as defined in Rule 3b-4 under the Exchange Act and its common shares are listed on Nasdaq. Nasdaq Marketplace Rule 5615(a)(3) permits a foreign private issuer to follow its home country practices in lieu of certain requirements in the Nasdaq Listing Rules. A foreign private issuer that follows home country practices in lieu of certain corporate governance provisions of the Nasdaq Listing Rules must disclose each Nasdaq corporate governance requirement that it does not follow and include a brief statement of the home country practice the issuer follows in lieu of the Nasdaq corporate governance requirement(s), either on its website or in its annual filings with the Commission. A description of the significant ways in which the Registrant’s corporate governance practices differ from those followed by domestic companies pursuant to the applicable Nasdaq Listing Rules is disclosed on the Registrant’s website at www.eupraxiapharma.com under “Investors/Governance/Governance Documents/Nasdaq Corporate Governance Disclosure.”

DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS

Not applicable.

RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION

Not applicable.

FORWARD-LOOKING STATEMENTS

Certain statements in this Annual Report on Form 40-F are forward-looking statements within the meaning of Section 21E of the Exchange Act and Section 27A of the Securities Act of 1933, as amended. Please see “CAUTION REGARDING FORWARD-LOOKING STATEMENTS AND RISK FACTORS” in the AIF, filed as Exhibit 99.1 to this Annual Report on Form 40-F for a discussion of risks, assumptions, uncertainties and other factors that could cause actual results to vary from those forward-looking statements.

UNDERTAKING

The Registrant undertakes to make available, in person or by telephone, representatives to respond to inquiries made by the Commission staff, and to furnish promptly, when requested to do so by the Commission staff, information relating to the securities in relation to which the obligation to file an annual report on Form 40-F arises or transactions in said securities.

CONSENT TO SERVICE OF PROCESS

The Registrant has previously filed a Form F-X in connection with the class of securities in relation to which the obligation to file this report arises.

Any change to the name or address of the Registrant’s agent for service shall be communicated promptly to the Commission by amendment to Form F-X referencing the file number of the Registrant.

Exhibit Index

Exhibit No. |  | Document
97.1 |  | Compensation Recovery Policy of the Registrant (incorporated by reference to Exhibit 97.1 to the Registrant’s Annual Report on Form 40-F for the fiscal year ended December 31, 2023).
99.1 |  | Annual Information Form of the Registrant for the fiscal year ended December 31, 2024.
99.2 |  | Consolidated Financial Statements as of and for the years ended December 31, 2024 and 2023.
99.3 |  | Management’s Discussion and Analysis of Financial Condition and Results of Operations for the year ended December 31, 2024.
99.4 |  | Consent of Independent Registered Public Accounting Firm – KPMG LLP
99.5 |  | Certification of Chief Executive Officer (Principal Executive Officer) pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
99.6 |  | Certification of Chief Financial Officer (Principal Financial Officer) pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
99.7 |  | Certification of Chief Executive Officer (Principal Executive Officer) under Section 906 of the Sarbanes-Oxley Act of 2002.
99.8 |  | Certification of Chief Financial Officer (Principal Financial Officer) under Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS |  | Inline XBRL Instance Document.
101.SCH |  | Inline XBRL Taxonomy Schema Linkbase Document.
101.CAL |  | Inline XBRL Taxonomy Calculation Linkbase Document.
101.DEF |  | Inline XBRL Taxonomy Definition Linkbase Document.
101.LAB |  | Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE |  | Inline XBRL Taxonomy Presentation Linkbase Document.
104 |  | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

SIGNATURES

Pursuant to the requirements of the Exchange Act, the Registrant certifies that it meets all of the requirements for filing on Form 40-F and has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.

Date: March 20, 2025

Eupraxia Pharmaceuticals Inc.
By: |  | /s/ James A. Helliwell
Name: James A. Helliwell
Title: Chief Executive Officer